New insider activity at RenovoRx ( (RNXT) ) has taken place on April 10, 2025.
CMO Ramtin Agah has made a significant investment in RenovoRx by purchasing 26,000 shares of the company’s stock, with the total transaction valued at $21,840.
Recent Updates on RNXT stock
RenovoRx has announced a delay in filing its Form 10-K for the financial period ending December 31, 2024, due to the need to complete certain technical accounting requirements. The company expects to file within the SEC’s fifteen-day grace period. Despite the delay, RenovoRx anticipates initial revenue from its RenovoCath commercial efforts and a slight decrease in net loss due to reduced expenses. H.C. Wainwright initiated coverage with a Buy rating, citing the company’s focus on developing a novel catheter system for targeted delivery of gemcitabine to treat pancreatic cancer. The firm sees potential in the company’s addressable market and future revenue growth, suggesting the shares are undervalued and appealing to long-term investors.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Underperform.
RenovoRx’s overall stock score reflects significant financial challenges, with persistent operational losses and negative cash flows. Technical analysis suggests ongoing bearish trends, while valuation is hampered by a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events further underscores the company’s uncertain outlook.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
YTD Price Performance: -41.18%
Average Trading Volume: 141,639
Technical Sentiment Signal: Strong Buy
Current Market Cap: $28.87M